CS
AZN icon

Comerica Securities’s AstraZeneca AZN Stock Holding History

Comerica Securities’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$409K Sell
3,022
-132
-4% -$18K 0.03% 307
2023
Q2 		$451K Sell
3,154
-209
-6% -$30.8K 0.03% 314
2023
Q1 		$467K Buy
3,363
+525
+18% +$70.6K 0.03% 307
2022
Q4 		$385K Buy
2,838
+138
+5% +$17.3K 0.03% 340
2022
Q3 		$296K Buy
2,700
+819
+44% +$104K 0.02% 347
2022
Q2 		$249K Sell
1,881
-896
-32% -$118K 0.02% 408
2022
Q1 		$368K Sell
2,777
-116
-4% -$13.9K 0.02% 366
2021
Q4 		$337K Buy
2,893
+116
+4% +$13.6K 0.02% 397
2021
Q3 		$334K Sell
2,777
-58
-2% -$6.75K 0.02% 386
2021
Q2 		$340K Sell
2,835
-283
-9% -$31K 0.03% 380
2021
Q1 		$310K Buy
+3,118
New +$313K 0.02% 403
2020
Q4 		– Sell
-2,545
Closed -$279K – 479
2020
Q3 		$279K Sell
2,545
-133
-5% -$14.8K 0.02% 355
2020
Q2 		$283K Sell
2,678
-147
-5% -$15.2K 0.03% 349
2020
Q1 		$252K Sell
2,825
-710
-20% -$66.8K 0.03% 344
2019
Q4 		$353K Sell
3,535
-96
-3% -$9.04K 0.03% 331
2019
Q3 		$324K Buy
3,631
+579
+19% +$50.2K 0.03% 333
2019
Q2 		$252K Buy
3,052
+288
+10% +$22.6K 0.03% 370
2019
Q1 		$223K Sell
2,764
-1,043
-27% -$82.2K 0.03% 392
2018
Q4 		$289K Sell
3,807
-977
-20% -$76.3K 0.04% 322
2018
Q3 		$379K Sell
4,784
-2,762
-37% -$209K 0.04% 316
2018
Q2 		$530K Sell
7,546
-590
-7% -$42.4K 0.06% 261
2018
Q1 		$569K Sell
8,136
-1,291
-14% -$89.4K 0.07% 251
2017
Q4 		$654K Buy
9,427
+774
+9% +$52.2K 0.08% 239
2017
Q3 		$586K Buy
8,653
+1,468
+20% +$92.7K 0.08% 235
2017
Q2 		$490K Buy
7,185
+1,341
+23% +$87.6K 0.07% 253
2017
Q1 		$364K Buy
+5,844
New +$340K 0.06% 287
2016
Q4 		– Sell
-3,147
Closed -$207K – 348
2016
Q3 		$207K Buy
+3,147
New +$206K 0.04% 333

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Comerica Securities's AZN Position: Q3 2023 in Review

Comerica Securities reduced its AstraZeneca (AZN) stake by 4.2% in Q3 2023, selling an estimated $18K and leaving 3,022 shares worth $409K. The position accounts for 0.03% of the portfolio, ranked #307.

Comerica Securities first reported a position in AZN in Q3 2016 and has held it in 27 quarters since. The position peaked at $654K in Q4 2017. 1,073 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

  • Comerica Securities held 3,022 shares of AstraZeneca worth $409K as of Q3 2023.
  • Comerica Securities sold 132 AstraZeneca shares in Q3 2023, an estimated $18K.
  • AstraZeneca made up 0.03% of Comerica Securities's portfolio in Q3 2023, its #307 holding.
  • Comerica Securities first reported a position in AstraZeneca in Q3 2016 and has held it in 27 quarters since.
  • Comerica Securities's AstraZeneca position peaked at $654K in Q4 2017.
  • 1,073 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Comerica Securities's 13F filing for Q3 2023, filed 26 Oct 2023.